Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2016 09:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 5,500,000 shares of its...
June 07, 2016 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

BURLINGTON, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other...
May 26, 2016 07:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Receives Positive Guidance from FDA on New Drug Application (NDA) Submission for Zilretta™ for Osteoarthritis of the Knee

BURLINGTON, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announces that yesterday it received written responses from the U.S. Food & Drug Administration...
May 12, 2016 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports First-Quarter 2016 Financial Results

Zilretta™, Flexion’s non-opioid lead drug candidate (also known as FX006), completed pivotal Phase 2b and Phase 3 clinical registration trials, in patients with osteoarthritis (OA) of the...
April 28, 2016 16:05 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Enrolls First Patient in Phase 2 Trial of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis

BURLINGTON, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its...
April 07, 2016 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at 15th Annual Needham Healthcare Conference

BURLINGTON, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a...
April 04, 2016 07:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Presentation of Results From Pivotal Phase 2b and Phase 3 Clinical Trials for Zilretta™ at Osteoarthritis Research Society International (OARSI) 2016 World Congress

Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain reliefIn the Phase 3 trial Zilretta, in...
April 01, 2016 17:07 ET | Source: Flexion Therapeutics, Inc.

Flexion to Present Pivotal Phase 2b and Phase 3 Results for Zilretta™ at Osteoarthritis Research Society International (OARSI) 2016 World Congress

BURLINGTON, Mass., April 01, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report results from the pivotal Phase 2b and Phase 3 clinical trials of...
March 10, 2016 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Reports Year-End 2015 Financial Results

Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta™, Flexion’s lead drug candidate (also known as FX006)Zilretta received Fast-Track designation by...
March 07, 2016 07:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at Cowen and Company’s 36th Annual Health Care Conference

BURLINGTON, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a...